Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-22T07:51:45.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Current and Future Treatments for Alzheimer's Disease

Published online by Cambridge University Press:  07 November 2014

Stephen Salloway
Get access Rights & Permissions [Opens in a new window]

Extract

There are currently >5 million people in the United States who have been diagnosed with Alzheimer's disease. That prevalence rate is expected to triple as the population ages. The health and economic burden due to Alzheimer's disease is a worldwide problem, with some of the greatest burden coming from the developing world as people live longer in those societies. Throughout the world, the projected growth of Alzheimer's disease is dramatic. This is a worldwide public health problem of the highest order, and there is a compelling need to develop new treatments and methods of earlier diagnosis need to slow the progression of the disease and lessen its impact.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S7: Mitochondria: An Emerging Therapeutic Focus in Alzheimer's Disease Therapy , August 2009 , pp. 4 - 7
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Alzheimer's Association. Alzheimer's Disease Facts and Figures. Available at: www.alz.org/alzheimers_disease_facts_figures.asp. Accessed July 2,2009.Google Scholar
2.Brookmeyer, R, Johnson, E, Ziegler-Grahamm, K, Arrighi, M.Forecasting the global prevalence and burden of Alzheimer's disease. Alzheimers Dement. 2007;3:S168–S169.Google Scholar
3.US Census Bureau News. Census Bureau Reports World's Older Population Projected to Triple by 2050. Washington. DC: US Census Bureau News; 2009. Available at: www.census.gov/Press-Reiease/www/releases/archives/international_population/013882.html. Accessed July 2, 2009.Google Scholar
4.Evans, DA, Funkenstein, HH, Albert, MS, et al.Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989:262(18):2551–2556.Google Scholar
5.von Strauss, E, Viitanen, M, De Ronchi, D, Winblad, B, Fratiglioni, L.Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999;56(5):587–592.CrossRefGoogle ScholarPubMed
6.Sofi, F, Cesari, F, Abbate, R, Gensini, GF, Casini, A.Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008;337:a1344.CrossRefGoogle ScholarPubMed
7.Stauffer, B.Alzheimer's Century: On the 100th anniversary of Dr. Alzheimer's discovery, new scientific advances fight a scourge of the 21st century. Neurology Now. 2006;2(2):34.Google Scholar
8.Rossor, MN, Iversen, LL, Reynolds, GP, Mountjoy, CO, Roth, M.Neurochemical characteristics of early and late onset types of Alzheimer's disease. BrMedJIClin Res Ed). 1984;288(6422):961–964.Google Scholar
9.Goedert, M, Spillantini, MG. A century of Alzheimer's disease. Science. 2006;314(5800):777–781.Google Scholar
10.Hansson, O, Zetterberg, H, Buchhave, P, Londos, E, Blennow, K, Minthon, L.Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–2234.Google Scholar
11.Klunk, WE, Engler, H, Nordberg, A, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.Google Scholar
12.Dubois, B, Feldman, HH, Jacova, C, et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.Google Scholar
13.Allain, H, Schück, S, Lebreton, S, et al.Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1999;10(3):181–185.Google Scholar
14.Tariot, PN, Farlow, MR, Grossberg, GT, Graham, SM, McDonald, S, Gergel, I, and the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–324.Google Scholar
15.Courtney, C, Farrell, D, Gray, R.et al, and the AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–2115.Google Scholar
16.Fillit, HM, Doody, RS, Binaso, K, et al.Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006;4(suppl A):S9–S24.Google Scholar
17.Finehout, EJ, Franck, Z, Choe, LH, Relkin, N, Lee, KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2007:61(2):120–129.Google Scholar
18.Aisen, PS. Gauthier, S, Vellas, B, et al.Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007;4(4):473–478.Google Scholar
19.Xaliproden: SR 57746, SR 57746A. xaliproden hydrochloride, xaliprodene. Drugs R D. 2003:4(6):386–388.Google Scholar
20.Woodman, R. Sanofi's Alzheimer's drug xaliproden fails in Phase 3. APM Health Europe. September 17, 2007. Available at: http://www.apmhealtheurope.com/story.php?mots=UPDATE&searchScope=1&searchType=0&numero=L8198. Accessed July 2. 2009.Google Scholar
21.Williams, M.Progress in Alzheimer's disease drug discovery: an update. Curr Opin Investig Drugs. 2009;10(1):23–34.Google Scholar
22.Jones, RW, Kivipelto, M, Feldman, H, et al, and the LEADe investigators. The Aton/astatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008;4(2):145–153.Google Scholar
23.Burton, A.9th International Conference on AD and related disorders (ICAD). Lancet Neurol. 2004;3(9):510.Google Scholar
24.Marder, K.Vaccine trial in Alzheimer's disease is halted. Curr Neurol Neurosci Rep. 2003:3(5):371–372.Google Scholar
25.Holmes, C., Boche, D, Wilkinson, D, et al.Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008:372(9634):216–223.Google Scholar
26.Brown, ME, DaSilva, KA, McLaurin, J.Refining an Alzheimer's vaccine to avoid an inflammatory response. Expert Opin Biol Ther. 2005;5(6):809–816.Google Scholar
27.ClinicalTrials.gov Identifier NCT00568776. ELND005 in Patients With Mild to Moderate Alzheimer's Disease. Available at: clinicaltrials.gov/ct2/show/NCT00568776. Accessed July 2, 2009.Google Scholar
28.Salloway, SMintzer, JWeiner, MF, Cummings, JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008;4(2):65–79.Google Scholar
29.Doody, RS, Gavrilova, SI, Sano, M, et al, and the dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.Google Scholar